Eurifel RCP FeLV

RSS

adjuvanted vaccine against feline viral rhinotracheitis, feline calicivirosis, feline panleucopenia and feline leukaemia.

Withdrawn
This medicine is now withdrawn from use in the European Union.

Overview

The marketing authorisation for Eurifel RCP FeLV has not been renewed by the marketing authorisation holder and is now withdrawn.

This EPAR was last updated on 23/07/2004

Authorisation details

Product details
Name
Eurifel RCP FeLV
Agency product number
EMEA/V/C/000067
Active substance
feline leukaemia virus / recombinant canarypox virus / attenuated feline panleucopenia virus / type 1 feline herpesvirus antigen / feline calicivirus antigen
International non-proprietary name (INN) or common name
adjuvanted vaccine against feline viral rhinotracheitis, feline calicivirosis, feline panleucopenia and feline leukaemia.
Species
Cats
Anatomical therapeutic chemical veterinary (ATCvet) codes
QI06AH
Publication details
Marketing-authorisation holder
Merial
Revision
8
Date of issue of marketing authorisation valid throughout the European Union
08/03/2002
Contact address
29, avenue Tony Garnier
69007 Lyon
FRANCE

Product information

23/07/2004 Eurifel RCP FeLV - EMEA/V/C/000067 -

Contents

  • Annex I - Summary of product characteristics
  • Annex IIA - Manufacturing-authorisation holder responsible for batch release
  • Annex IIB - Conditions of the marketing authorisation
  • Annex IIIA - Labelling
  • Annex IIIB - Package leaflet

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Immunologicals for felidae

Therapeutic indication

Vaccine against feline viral rhinotracheitis, feline calicivirosis, feline panleucopenia and feline leukaemia.

Stimulates active immunity against feline rhinotracheitis virus, feline calicivirus, feline panleucopenia virus and feline leukaemia virus.

The feline leukaemia vaccine strain is a recombinant canarypox virus expressing the env and gag genes of FeLV-A. Under field conditions, only sub-group A is infective and immunisation against subgroup A provides full protection against A, B and C. After inoculation, the virus expresses the protective proteins, but does not replicate in the cat. As a consequence, the vaccine induces an immune status against feline leukaemia virus.

How useful was this page?

Add your rating